Page last updated: 2024-09-05

sorafenib and Pulmonary Arterial Remodeling

sorafenib has been researched along with Pulmonary Arterial Remodeling in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hikasa, Y; Leong, ZP	1

Other Studies

1 other study(ies) available for sorafenib and Pulmonary Arterial Remodeling

Article	Year
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats. Vascular pharmacology, 2018, Volume: 110 Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Indoles; Male; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pulmonary Artery; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling	2018

Article

Year

Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.

Vascular pharmacology, 2018, Volume: 110

Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Indoles; Male; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pulmonary Artery; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling

2018